Samsung Epis Holdings introduced on Nov. 11 that it has established a subsidiary EPIS NexLab to pursue future bio new progress companies. EPIS NexLab plans to advance biotechnology platform improvement tasks in numerous fields together with amino acid conjugates (peptides) with out distinguishing experience and bounds.
EPIS NexLab is a subsidiary created following the launch of bio funding holding firm Samsung Epis Holdings on Nov. 1 by a spin-off from Samsung Biologics. Concerning the corporate title, the corporate defined that primarily based on the company id of EPIS, derived from “EPISTEME,” which suggests the essence of science and data in Greek, it symbolizes a versatile and future-oriented imaginative and prescient as an organization researching next-generation applied sciences.
The biotechnology platform enterprise that EPIS NexLab pursues refers to creating extremely scalable core applied sciences to derive a number of biopharmaceutical candidate substances. The inspiration is a biotech enterprise mannequin that develops platforms, discovers new drug candidates primarily based on them, and secures income by this course of. In keeping with the corporate’s clarification, it possesses excessive enterprise scalability as it may be utilized to varied illness areas with out being restricted to particular medication or indications. EPIS NexLab plans to pursue joint improvement or know-how switch with world pharmaceutical firms primarily based on platform know-how, and also will actively broaden open innovation within the world market.
EPIS NexLab CEO can be concurrently served by Hong Sung-won, head of Growth Division 1 at Samsung Bioepis. He’s a bio R&D knowledgeable from world pharmaceutical firms who beforehand served as director at Regeneron Prescription drugs, head of the New Drug Analysis Middle at LG Chem, and head of the International Innovation Middle. He’s scheduled to additionally function a non-executive director of Samsung Epis Holdings, taking part within the holding firm’s board actions.
Hong acknowledged, “EPIS NexLab will uncover future new progress drivers for Samsung Epis Holdings throughout the secure enterprise construction below the holding firm and lead technological innovation within the bio business by daring challenges.”
In the meantime, Samsung Epis Holdings plans to pursue numerous promising bio new companies with Samsung Bioepis, which develops and commercializes biopharmaceuticals, and EPIS NexLab, which develops biotechnology platforms, as respective subsidiaries.
